Takeda Files For DPP-4 Combo Tablet In U.S., Establishes Asia Hub In Singapore
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Takeda Pharmaceutical said Sept. 24 its U.S. R&D subsidiary, Takeda Global Research & Development Center, had applied to the U.S. Food and Drug Administration for approval to market an alogliptin/Actos combination tablet for the treatment of type 2 diabetes
You may also be interested in...
Takeda’s Alogliptin Strategy: Treatment Options
With patent protection for its blockbuster insulin-resistance drug Actos (pioglitazone) set to expire in 2011, Takeda is testing its new Type 2 diabetes candidate, alogliptin, in several therapeutic settings to give physicians confidence the drug will fit into a variety of treatment plans
Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market
Takeda submitted an NDA for its dipeptidyl peptidase-4 inhibitor alogliptin (SYR-322) for type 2 diabetes Dec. 27, potentially positioning the Japanese pharma to be second to market with a drug in the class
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).